59 results
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research … by reference herein, including statements regarding our future results of operations and financial position, business strategy, prospective products
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
CRINETICS PHARMACEUTICALS | Phase 3 design strategy
Carcinoid Syndrome is a Serious Disease and Patients Need Better Treatment Options NETs … syndrome.
Strategy to Enable Paltusotine to Serve a Greater Number of Patients Acromegaly (11,000) Carcinoid Syndrome Switching from Depots (10,000
8-K
EX-10.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
Trust
T. Rowe Price U.S. Equities Trust
T. Rowe Price Multi-Strategy Total Return Fund, Inc.
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund … to Securities Purchase Agreement]
PURCHASER:
DESTINATIONS MULTI STRATEGY ALTERNATIVES FUND
By:
/s/ Janet McWilliams
Name:
Janet McWilliams
Title
8-K
EX-10.2
oy86nxn2tstx2c75
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
424B5
jsntc4nxkemhd244k8rk
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
b7j poqpprzqojo4
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
h652h
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
424B5
5ve2kv0h889
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
EX-99.1
lq3ivm0a71fy4x553px3
25 May 22
Regulation FD Disclosure
7:02am